Literature DB >> 24076547

Treatment of refractory sclerodermatous chronic graft-versus-host disease with intravenous lidocaine infusions.

C Phipps1, M T Lupo-Stanghellini2, M E D Flowers3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24076547     DOI： 10.1038/bmt.2013.159

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion.

Authors:  J C Voltarelli; H Ahmed; E J Paton; A B Stracieri; P Holman; A Bashey; M Coutinho; B P Simoes; E D Ball; E Carrier
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

2.  Possible involvement of cytokines, chemokines and chemokine receptors in the initiation and progression of chronic GVHD.

Authors:  J-N Hayashida; S Nakamura; T Toyoshima; M Moriyama; M Sasaki; E Kawamura; Y Ohyama; W Kumamaru; K Shirasuna
Journal:  Bone Marrow Transplant       Date:  2012-06-04       Impact factor: 5.483

3.  Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

Authors:  Adèle de Masson; Jean-David Bouaziz; Régis Peffault de Latour; Sebastian Wittnebel; Patricia Ribaud; Marie-Thérèse Rubio; Jean-Baptiste Micol; Felipe Suarez; Stéphanie Nguyen; Jean-Hugues Dalle; Karima Yakouben; Marie Robin; Aliénor Xhaard; Lionel Adès; Jean-Henri Bourhis; Michel Rybojad; Martine Bagot; Gérard Socié
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

4.  Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Effie W Petersdorf; J Lee Nelson; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; John A Hansen; Paul J Martin; Mary E D Flowers
Journal:  Blood       Date:  2013-04-01       Impact factor: 22.113

5.  Lidocaine down-regulates nuclear factor-kappaB signalling and inhibits cytokine production and T cell proliferation.

Authors:  A Lahat; S Ben-Horin; S B Horin; A Lang; E Fudim; O Picard; Y Chowers
Journal:  Clin Exp Immunol       Date:  2008-03-18       Impact factor: 4.330

6.  Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Barry Storer; Paul Carpenter; Andrew R Rezvani; Afonso C Vigorito; Paulo V Campregher; Carina Moravec; Hans-Peter Kiem; Matthew Fero; George Georges; Edus Warren; Stephanie Lee; Jean E Sanders; Fred Appelbaum; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

7.  [Some little-known conservative methods of treatment of Raynaud's syndrome].

Authors:  H R Van Der Molen; K Balmus
Journal:  Phlebologie       Date:  1977 Apr-Jun

Review 8.  More than skin deep? Emerging therapies for chronic cutaneous GVHD.

Authors:  C J Rodgers; S Burge; J Scarisbrick; A Peniket
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

9.  Local anesthetic lidocaine inhibits the effect of granulocyte colony-stimulating factor on human neutrophil functions.

Authors:  A Ohsaka; K Saionji; N Sato; J Igari
Journal:  Exp Hematol       Date:  1994-05       Impact factor: 3.084

10.  Lidocaine for systemic sclerosis: a double-blind randomized clinical trial.

Authors:  Rachel Riera; Luís E C Andrade; Alexandre W S Souza; Cristiane Kayser; Edison T Yanagita; Virgínia F M Trevisani
Journal:  Orphanet J Rare Dis       Date:  2011-02-07       Impact factor: 4.123
  10 in total
  1 in total

1.  New water-soluble palladium(II) complexes of lidocaine and phenylcyanamide derivative ligands: cytotoxicity and cellular response mechanisms.

Authors:  Leila Tabrizi; Hossein Chiniforoshan
Journal:  Invest New Drugs       Date:  2016-09-19       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.